Denali therapeutics announces strategic partner takeda exercises option to co-develop and co-commercialize dnl593 (ptv:pgrn)

— companies to advance clinical development of dnl593 as a brain-penetrant progranulin replacement therapy for frontotemporal dementia-granulin (ftd-grn) —

DNLI Ratings Summary

DNLI Quant Ranking